Total Domination Dot Critical and Dot Stable Graphs.

Two vertices are said to be identifed if they are combined to form one vertex whose neighborhood is the union of their neighborhoods. A graph is total domination dot-critical if identifying any pair of adjacent vertices decreases the total domination number. On the other hand, a graph is total domination dot-stable if identifying any pair of adjacent vertices leaves the total domination number unchanged. Identifying any pair of vertices cannot increase the total domination number. Further we show it can decrease the total domination number by at most two. Among other results, we characterize total domination dot-critical trees with total domination number three and all total domination dot-stable graphs

The Grizzly, December 5, 1995

Concerns About Commencement • Bohanak Injured in Accident • Dean Search Committee Appointed • Science: Fact or Fiction? • Lower Prices = Lower Quality • No One is Going to Starve • Religion as a Basis for Morality? • Fun With the Subjunctive • Letters to the Editor • The Beatles Anthology • Messiah a Success • Bears Surprise NYU • Bears Open Conference Play with Two Wins • Ortman Starts Season with a Bang • Teams Begin Season with Winshttps://digitalcommons.ursinus.edu/grizzlynews/1371/thumbnail.jp

The Grizzly, February 27, 1996

Koestner Gives First-Hand Account of Date Rape • J-Board Charges Reimert Residents • Swastikas are Removed from Bomberger Hall • Buchanan Wins New Hampshire • The Skipped Diploma • Evolutionary Doubts • Fighting for Real Social Change • In Support of Healthier Relationships • Alan Morrison to Perform Recital • U.S.G.A. News • Faculty Spotlight: Dr. Peter Perreten • Staff Spotlight: Todd McKinney • Gymnasts End Season With a Win • Lacrosse Team Ranked 15th • Bears Compete at Indoor Championships • Lady Bears Fall in Conference Semishttps://digitalcommons.ursinus.edu/grizzlynews/1376/thumbnail.jp

The Grizzly, November 7, 1995

The Inauguration of President John Strassburger • Colloquium Report • Dilemma After Dark • The Truth About the Honor Code • Canned Food Drive a Success • Rabin Assassinated • Canada Remains Unified • Enough is Enough • Dr. Oboler Responds • Homosexuality: It Doesn\u27t Have to Last Forever • There is More Than One Christian View • A Parent\u27s View • A Big Thank You! • Inauguration Day • Making Ursinus Whole • And the Verdict is... • New Additions in Zack\u27s • Snell Cup Comes Home • Season Ends with Win • Football Team Avoids Centennial Cellarhttps://digitalcommons.ursinus.edu/grizzlynews/1368/thumbnail.jp

Elicitation of expert prior opinion:application to the MYPAN trial in childhood polyarteritis nodosa

Objectives Definitive sample sizes for clinical trials in rare diseases are usually infeasible. Bayesian methodology can be used to maximise what is learnt from clinical trials in these circumstances. We elicited expert prior opinion for a future Bayesian randomised controlled trial for a rare inflammatory paediatric disease, polyarteritis nodosa (MYPAN, Mycophenolate mofetil for polyarteritis nodosa). Methods A Bayesian prior elicitation meeting was convened. Opinion was sought on the probability that a patient in the MYPAN trial treated with cyclophosphamide would achieve disease remission within 6-months, and on the relative efficacies of mycophenolate mofetil and cyclophosphamide. Expert opinion was combined with previously unseen data from a recently completed randomised controlled trial in ANCA associated vasculitis. Results A pan-European group of fifteen experts participated in the elicitation meeting. Consensus expert prior opinion was that the most likely rates of disease remission within 6 months on cyclophosphamide or mycophenolate mofetil were 74% and 71%, respectively. This prior opinion will now be taken forward and will be modified to formulate a Bayesian posterior opinion once the MYPAN trial data from 40 patients randomised 1:1 to either CYC or MMF become available. Conclusions We suggest that the methodological template we propose could be applied to trial design for other rare diseases

The Grizzly, February 20, 1996

Talk Show Trouble • Major Fair 1996 • J.D. Salinger: A Grizzly Staffer!; The Skipped Diploma • Boxer Tommy Morrison HIV-Positive • Swedish Vocal Ensemble to Perform • Meet the Candidates: A Largely Biased Commentary • Take it Back, Captain Jack? • Blatant Generalizations • You Bet Your Life • Confessions of a Computer Dork • To Bus or Not to Bus • Vicki Abt Revisited • Free Speech, Abortion, and Presidential Politics • Valentine\u27s Spectacular Brings Elegant Dining to Zack\u27s • WVOU: State of the Nation • Airband Proceeds to Help Student Ryan Auch • Guys Come Up Short in Muhlenberg • Lady Bears Get Crushed by Muhlenberg • Bears Place Four at Eastern Regionalshttps://digitalcommons.ursinus.edu/grizzlynews/1375/thumbnail.jp

Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa.

OBJECTIVES: Definitive sample sizes for clinical trials in rare diseases are usually infeasible. Bayesian methodology can be used to maximise what is learnt from clinical trials in these circumstances. We elicited expert prior opinion for a future Bayesian randomised controlled trial for a rare inflammatory paediatric disease, polyarteritis nodosa (MYPAN, Mycophenolate mofetil for polyarteritis nodosa). METHODS: A Bayesian prior elicitation meeting was convened. Opinion was sought on the probability that a patient in the MYPAN trial treated with cyclophosphamide would achieve disease remission within 6-months, and on the relative efficacies of mycophenolate mofetil and cyclophosphamide. Expert opinion was combined with previously unseen data from a recently completed randomised controlled trial in ANCA associated vasculitis. RESULTS: A pan-European group of fifteen experts participated in the elicitation meeting. Consensus expert prior opinion was that the most likely rates of disease remission within 6 months on cyclophosphamide or mycophenolate mofetil were 74% and 71%, respectively. This prior opinion will now be taken forward and will be modified to formulate a Bayesian posterior opinion once the MYPAN trial data from 40 patients randomised 1:1 to either CYC or MMF become available. CONCLUSIONS: We suggest that the methodological template we propose could be applied to trial design for other rare diseases

Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial

Inducing antiretroviral therapy (ART)-free virological control is a critical step toward a human immunodeficiency virus type 1 (HIV-1) cure. In this phase 2a, placebo-controlled, double-blinded trial, 43 people (85% males) with HIV-1 on ART were randomized to (1) placebo/placebo, (2) lefitolimod (TLR9 agonist)/placebo, (3) placebo/broadly neutralizing anti-HIV-1 antibodies (bNAbs) or (4) lefitolimod/bNAb. ART interruption (ATI) started at week 3. Lefitolimod was administered once weekly for the first 8 weeks, and bNAbs were administered twice, 1 d before and 3 weeks after ATI. The primary endpoint was time to loss of virologic control after ATI. The median delay in time to loss of virologic control compared to the placebo/placebo group was 0.5 weeks (P = 0.49), 12.5 weeks (P = 0.003) and 9.5 weeks (P = 0.004) in the lefitolimod/placebo, placebo/bNAb and lefitolimod/bNAb groups, respectively. Among secondary endpoints, viral doubling time was slower for bNAb groups compared to non-bNAb groups, and the interventions were overall safe. We observed no added benefit of lefitolimod. Despite subtherapeutic plasma bNAb levels, 36% (4/11) in the placebo/bNAb group compared to 0% (0/10) in the placebo/placebo group maintained virologic control after the 25-week ATI. Although immunotherapy with lefitolimod did not lead to ART-free HIV-1 control, bNAbs may be important components in future HIV-1 curative strategies. ClinicalTrials.gov identifier: NCT03837756